What is the life expectancy for stage 4 prostate cancer?

Reviewed by Yoshinori Abe, MD

Internal Medicine

Stage 4 prostate cancer, or metastatic prostate cancer, has a median life expectancy of approximately 2 to 3 years after diagnosis. However, survival rates vary widely based on key factors such as overall health, cancer aggressiveness, PSA levels, treatment response, and where the cancer has spread. Many patients live significantly longer thanks to advances in hormone therapy, chemotherapy, immunotherapy, and targeted treatments. Early detection and personalized care plans can meaningfully improve outcomes and quality of life.

If you're experiencing symptoms that concern you or want clarity about your health, don't wait in uncertainty. A free, instant, online symptom check can help you understand what your symptoms may mean, identify possible conditions, and guide your next steps—whether that's seeing a specialist, requesting specific tests, or preparing questions for your doctor. Taking a few minutes now could make all the difference in catching issues early and getting the right care sooner.

Reviewed for medical accuracy: 07/14/2026

Important Next Steps

Understand your stage 4 prognosis factors See stage 4 prostate cancer treatment options Discover best OTC medication options for symptoms Learn your eligibility for clinical trials

Not seeing your question? No worries.

Submit your own Question

Explanation

Understanding Stage 4 Prostate Cancer

Stage 4 prostate cancer indicates that the cancer has spread beyond the prostate gland to other parts of the body, such as bones, lymph nodes, or other organs. This stage is often associated with more severe symptoms and a poorer prognosis compared to earlier stages.

Survival Rates and Life Expectancy

Median Survival: Research indicates that the median survival for patients with stage 4 prostate cancer is around 2 to 3 years. However, this can vary widely among individuals (Siegel et al., 2020; Würnschimmel et al., 2021).
Five-Year Survival Rate: The five-year survival rate for patients with metastatic prostate cancer is approximately 30%. This means that about 30% of patients diagnosed with stage 4 prostate cancer are expected to live for at least five years after diagnosis (Lin et al., 2023).

Factors Influencing Life Expectancy

Several factors can influence the life expectancy of patients with stage 4 prostate cancer:

Age and Overall Health: Younger patients and those in better overall health may have a better prognosis and longer survival.
Response to Treatment: Advances in treatment options, including hormone therapy, chemotherapy, and newer targeted therapies, can significantly impact survival rates. Patients who respond well to these treatments may live longer.
Racial and Ethnic Factors: Studies have shown that survival rates can vary among different racial and ethnic groups, with some groups experiencing better outcomes than others (Würnschimmel et al., 2021).

Importance of Ongoing Care

Patients with stage 4 prostate cancer should work closely with their healthcare team to develop a personalized treatment plan. If you're experiencing concerning symptoms, you can use a free symptom checker to help identify potential issues before your next medical appointment. Regular follow-ups and monitoring can help manage symptoms and improve quality of life. Palliative care options are also available to support patients and their families during this challenging time.

(References)

Siegel DA, O'Neil ME, Richards TB, Dowling NF, Weir HK. Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017. MMWR Morb Mortal Wkly Rep. 2020 Oct 16;69(41):1473-1480. doi: 10.15585/mmwr.mm6941a1. PMID: 33056955; PMCID: PMC7561091.
Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, Briganti A, Shariat SF, Mirone V, Chun FK, Tilki D, Graefen M, Karakiewicz PI. Life expectancy in metastatic prostate cancer patients according to racial/ethnic groups. Int J Urol. 2021 Aug;28(8):862-869. doi: 10.1111/iju.14595. Epub 2021 May 15. PMID: 33993551.
Lin J, Nousome D, Jiang J, Chesnut GT, Shriver CD, Zhu K. Five-year survival of patients with late-stage prostate cancer: comparison of the Military Health System and the U.S. general population. Br J Cancer. 2023 Apr;128(6):1070-1076. doi: 10.1038/s41416-022-02136-3. Epub 2023 Jan 6. PMID: 36609596; PMCID: PMC10006403.

Thinking about asking ChatGPT?Ask me instead

Tell your friends about us.

We would love to help them too.

For First Time Users

What is Ubie’s Doctor’s Note?

We provide a database of explanations from real doctors on a range of medical topics. Get started by exploring our library of questions and topics you want to learn more about.

Was this page helpful?

Purpose and positioning of servicesUbie Doctor's Note is a service for informational purposes. The provision of information by physicians, medical professionals, etc. is not a medical treatment. If medical treatment is required, please consult your doctor or medical institution. We strive to provide reliable and accurate information, but we do not guarantee the completeness of the content. If you find any errors in the information, please contact us.